Abstract
Huntington’s disease (or chorea) is a progressive, inherited neurodegenerative disease characterized by autosomal dominant transmission and the emergence of abnormal involuntary movements and cognitive deterioration, with progression to dementia and death over 10–20 yr; the gene responsible, huntingtin, is located on chromosome 4 (Harper, 1996; Huntington’s Disease Collaborative Research Group, 1993). Until the studies using eicosapentaenoic acid, there was no evidence of effective treatment for this disorder.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bydder, G. M. (1995). The Mackenzie Davidson Memorial Lecture: Detection of small changes to the brain with serial magnetic resonance imaging. British Journal of Radiology, 68, 1271–1295.
Bydder, G. M., & Hajnal, J. V. (1997). Registration and subtraction of serial MRI—Part 2: Image interpretation. In W. G. Bradley & G. M. Bydder (Eds.), Advanced MR imaging techniques (pp. 239–258). London: Martin Dunitz.
Clifford, J. J., Drago, J., Natoli, A. L., Wong, J. Y., Kinsella, A., Waddington, J. L. & Vaddadi, K. S. (2002). Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington’s disease. Neuroscience, 109, 81–88.
Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997). Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell, 90, 537–548.
Ellison, D. W., Beal, M. F., & Martin, J. B. (1987). Phosphoethanolamine and ethanolamine are decreased in Alzheimer’s disease and Huntington’s disease. Brain Research, 417, 389–392.
Harper, P. S., (Ed.). (1996). Huntington’s disease, (2nd ed.). London: W. B. Saunders.
Huntington Study Group. (1996). Unified Huntington’s Disease Rating Scale: Reliability and consistency. Movement Disorders, 11, 136–142.
Huntington’s Disease Collaborative Research Group. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell, 72, 971–983.
Klivenyi, P., Beal, M. F., Ferrante, R. J., Andreassen, O. A., Wermer, M., Chin, M. R., & Bonventre, J. V. (1998). Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. Journal of Neurochemistry, 71, 2634–2637.
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., & Bates, G. P. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493–506.
Puri, B. K. (2001). Impaired phospholipid-related signal transduction in advanced Huntington’s disease. Experimental Physiology, 86, 683–685.
Puri, B. K. (2004). Monomodal rigid-body registration and applications to the investigation of the effects of eicosapentaenoic acid intervention in neuropsychiatric disorders. Prostaglandins, Leukotrienes and Essential Fatty Acids, 71, 177–179.
Puri, B. K., Bydder, G. M., Counsell, S. J., Corridan, B. J., Richardson, A. J., Hajnal, J. V., Appel, C., McKee, H. M., Vaddadi, K. S., & Horrobin, D. F. (2002). MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport, 13, 123–126.
Puri, B. K., Counsell, S. J., Hamilton, G., Richardson, A. J., & Horrobin, D. F. (2001). Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced neuronal phospholipid turnover. International Journal of Clinical Practice, 55, 560–563.
Puri, B. K., Hirsch, S. R., Easton, T., & Richardson, A. J. (2002). A volumetric biochemical niacin flush-based index that noninvasively detects fatty acid deficiency in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry, 26, 49–52.
Puri, B. K., Leavitt, B. R., Hayden, M. R., Ross, C. A., Rosenblatt, A., Greenamyre, J. T., Hersch, S., Vaddadi, K. S., Sword, A., Horrobin, D. F., & Murck, H. (2005). Ethyl-EPA in Huntington’s disease: A double-blind, randomized, placebo-controlled trial. Neurology (in press).
Puri, B. K., & Richardson, A. J. (1998). Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. Archives of General Psychiatry, 55, 188–189.
Puri, B. K., Richardson, A. J., Horrobin, D. F., Easton, T., Saeed, N., Oatridge, A., Hajnal, J. V., & Bydder, G. M. (2000). Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. International Journal of Clinical Practice, 54, 57–63.
Saeed, N., Puri, B. K., Oatridge, A., Hajnal, J. V., & Young, I. R. (1998). Two methods for semi-automated quantification of changes in ventricular volume and their use in schizophrenia. Magnetic Resonance in Medicine, 16, 1237–1247.
Sakai, T., Antoku, Y., Iwashita, H., Goto, I., Nagamatsu, K., & Shii, H. (1991). Chorea-acanthocytosis: Abnormal composition of covalently bound fatty acids of erythrocyte membrane proteins. Annals of Neurology, 29, 664–669.
Vaddadi, K. (2003). Essential fatty acids in the treatment of Huntington’s disease. In M. Pett, I. Glen, & D. F. Horrobin (Eds.), Phospholipid spectrum disorder in psychiatry and neurology (2nd ed.). (pp. 565–574). Carnforth, Lancashire: Marius.
Vaddadi, K. S., Soosai, E., Chiu, E., & Dingjan, P. (2002). A randomised, placebo-controlled, double blind study of treatment of Huntington’s disease with unsaturated fatty acids. Neuroreport, 13, 29–33.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Puri, B.K. (2006). Treatment of Huntington’s Disease With Eicosapentaenoic Acid. In: Yehuda, S., Mostofsky, D.I. (eds) Nutrients, Stress, and Medical Disorders. Nutrition and Health. Humana Press. https://doi.org/10.1385/1-59259-952-4:279
Download citation
DOI: https://doi.org/10.1385/1-59259-952-4:279
Publisher Name: Humana Press
Print ISBN: 978-1-58829-432-6
Online ISBN: 978-1-59259-952-3
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)